Diabetic Nephropathy
📧 Sign up to get email alerts when something new happens for Diabetic Nephropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-12-07Clinical Trial Update: The Effects of TMZ on Diabetic Nephropathy [Phase 2]
Phase 2 trial updating the effects of temozolomide (TMZ) on diabetic nephropathy is ongoing with unknown status.
-
FDA approval · 2021-12-06FDA Approved: VALSARTAN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for valsartan submitted by Aurobindo Pharma Limited, updating the existing approval for this generic…
-
FDA approval · 2021-12-03FDA Approved: IRBESARTAN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for irbesartan submitted by Lupin Pharmaceuticals, Inc.
-
FDA approval · 2021-09-14FDA Approved: IRBESARTAN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for IRBESARTAN, a generic angiotensin II receptor blocker.
-
FDA label_change · 2021-09-10FDA Approved: AVAPRO — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental labeling change for AVAPRO (irbesartan) filed by Sanofi-Aventis U.S. LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-09-01FDA Approved: IRBESARTAN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for IRBESARTAN from Aurobindo Pharma Limited under ANDA 203081.
-
CLINICAL_TRIALS trial_result · 2021-08-31Clinical Trial Update: Evaluation of Coffee Therapy for Improvement of Renal Oxygenation [Phase 2]
Phase 2 clinical trial evaluating coffee therapy to improve renal oxygenation; completed with posted results.
-
FDA approval · 2021-08-26FDA Approved: IRBESARTAN — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved a supplemental application for IRBESARTAN filed by Unichem Pharmaceuticals (USA), Inc., effectively updating the existing A…
-
CLINICAL_TRIALS trial_result · 2021-08-25Clinical Trial Update: Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy [Phase 2]
A Phase 2 clinical trial evaluating safety, tolerability, and renal effects of APX-115 in subjects with type 2 diabetes and nephropathy has …
-
CLINICAL_TRIALS trial_result · 2021-08-23Clinical Trial Update: European Trial of Immunosuppression in SPK Tx [Phase 3]
Phase 3 trial update of immunosuppression in simultaneous kidney-pancreas transplantation has completed.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients [Phase 2]
Phase 2 study evaluating safety and efficacy of CTP-499 in patients with type 2 diabetic nephropathy (type 2 diabetes mellitus with chronic …
-
FDA approval · 2021-08-05FDA Approved: ENALAPRIL MALEATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for enalaprilate maleate from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., effecti…
-
CLINICAL_TRIALS trial_result · 2021-07-16Clinical Trial Update: Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan) [Phase 2]
Phase 2 trial update evaluating safety and efficacy of different oral doses of BAY94-8862 in Japanese subjects with type 2 diabetes and diab…
-
CLINICAL_TRIALS trial_result · 2021-05-11Clinical Trial Update: CPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea [Phase 4]
Phase 4 trial updating the effect of continuous positive airway pressure (CPAP) on albuminuria in patients with diabetic nephropathy and obs…
-
FDA approval · 2021-05-06FDA Approved: IRBESARTAN — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for IRBESARTAN by NorthStar RxLLC, indicating an update to the label or expanded indication.
-
FDA approval · 2021-05-06FDA Approved: IRBESARTAN — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for IRBESARTAN from Camber Pharmaceuticals for the generic irbesartan product, indicating an approve…
-
FDA approval · 2021-04-30FDA Approved: CANDESARTAN CILEXETIL — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for candesartan cilexetil from Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS research · 2021-04-30Clinical Trial Update: Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy [Phase 2, Phase 3]
Phase 2/3 trial investigating semi-individualised Chinese medicine as an adjuvant treatment for diabetic nephropathy.
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) [Phase 4]
Phase 4 clinical trial update on the effect of sarpogrelate in diabetic nephropathy, completed.
-
FDA approval · 2021-04-23FDA Approved: IRBESARTAN — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved a supplemental application for Irbesartan from Unichem Pharmaceuticals USA, Inc., indicating regulatory approval of a modif…
-
CLINICAL_TRIALS trial_result · 2021-03-19Clinical Trial Update: Effect of Sulodexide in Overt Diabetic Nephropathy [Phase 4]
Phase 4 trial update for sulodexide in overt diabetic nephropathy; study terminated.
-
CLINICAL_TRIALS trial_result · 2021-02-16Clinical Trial Update: Possible Role of Roflumilast in Diabetic Nephropathy [Phase 3]
A Phase 3 clinical trial is investigating the possible role of roflumilast in diabetic nephropathy; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes [Phase 4]
Phase 4 trial assessing acute renal oxygenation and autonomic function effects of SGLT2 inhibition in type 1 diabetes.
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Magnesium Supplementation in Diabetic Nephropathy [Phase 2]
Phase 2 clinical trial on magnesium supplementation for diabetic nephropathy has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN) [Phase 3]
A Phase 3 clinical trial assessing metabolic effects of empagliflozin in patients with diabetic nephropathy was terminated.